Hemophagocytic Lymphohistiocytosis
10.15264/cpho.2017.24.1.11
- Author:
Sun Young PARK
1
;
Jae Min LEE
Author Information
1. Department of Pediatrics, College of Medicine, Yeungnam University, Daegu, Korea. mopic@yu.ac.kr
- Publication Type:Review
- Keywords:
Hemophagocytic lymphohistiocytosis;
Genetics;
Pathogenesis;
Treatment
- MeSH:
Diagnosis;
Genetics;
Humans;
Immune System;
Immunosuppression;
Inflammation;
Lymphohistiocytosis, Hemophagocytic;
Treatment Outcome
- From:Clinical Pediatric Hematology-Oncology
2017;24(1):11-20
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Hemophagocytic lymphohistiocytosis (HLH) is a potentially fatal disease caused by dysregulated immune responses and overwhelming inflammation to infectious or other triggers of the immune system. HLH may be inherited (primary) or may be secondary to any severe infection, malignancy or rheumatologic disease. Clinical progress of HLH is usually rapid and fatal. Early recognition and assessment of potential causes of HLH is critical to improve survival. Urgent treatment is needed for immunosuppression and degradation of the activated antigen. Over the last two decades, research on genetics and pathophysiology of HLH has much improved treatment outcome of the patient. Here, we review recent advances in our understanding of etiology, pathophysiology, diagnosis and treatment of HLH.
